-
RISING LEVELS OF INNOVATION IN EXPEDITED DESIGNATIONS AMONG FDA-APPROVED DRUGS: 2012-2024
Mar 18, 2026, 21:38 PM -
YEARS LOST: QUANTIFYING THE HUMAN COST OF DELAYED GENETIC DIAGNOSIS
Mar 18, 2026, 21:38 PM -
THE ROLE OF SAFETY AND TOLERABILITY IN HTA VALUE ASSESSMENT: EVIDENCE REQUIREMENTS AND IMPACT ACROSS KEY EUROPEAN MARKETS
Mar 18, 2026, 21:38 PM -
A MULTI-DIMENSIONAL WEIGHTING METHODOLOGY FOR EVALUATING PATIENT-REPORTED OUTCOME EVIDENCE TO OPTIMIZE AND DIFFERENTIATE A MARKETED TREATMENT
Mar 18, 2026, 21:38 PM -
HEOR IN THE ABSENCE OF A CODE-BASED POPULATION DEFINITION
Mar 18, 2026, 21:38 PM -
GEOGRAPHIC DISPARITIES IN TREATMENT ACCESS FOR TEXAS MEDICAID PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS AND BUDGET IMPACT OF THE ETONOGESTREL SUBDERMAL IMPLANT INCORPORATING REAL-WORLD UTILIZATION DATA FROM A LARGE BRAZILIAN PRIVATE HEALTH INSURER
Mar 18, 2026, 21:38 PM -
EARLY-LIFE PAIN EXPERIENCES AND DEPRESSION ONSET AMONG CHILDREN WITH SICKLE CELL DISEASE A LONGITUDINAL ANALYSIS USING TEXAS MEDICAID DATA
Mar 18, 2026, 21:38 PM -
EVALUATING THE PATIENT BURDEN ASSOCIATED WITH DELAYED REIMBURSEMENT: A CASE STUDY OF PEMBROLIZUMAB IN THE TREATMENT OF ENDOMETRIAL CANCER IN CANADA
Mar 18, 2026, 21:38 PM -
GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS AND RISK OF PARKINSON’S DISEASE IN PATIENTS WITH OBESITY
Mar 18, 2026, 21:38 PM -
ASSOCIATION BETWEEN INTRA- AND POST-OPERATIVE HEMOSTASIS-RELATED COMPLICATIONS AND HEALTH ECONOMIC OUTCOMES IN PATIENTS UNDERGOING MYOMECTOMY: A RETROSPECTIVE DATABASE ANALYSIS
Mar 18, 2026, 21:38 PM -
IDENTIFYING ONCOLOGY PATIENT SUBTYPES USING ELECTRONICPATIENT-REPORTED OUTCOMES (EPROS)DEPLOYED INCLINICAL PRACTICE: A PATIENT-CENTRIC APPROACH TO MACHINE LEARNING
Mar 18, 2026, 21:38 PM -
REAL-WORLD TREATMENT PATTERNS AND TREATMENT INTENSIFICATION IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) BY DISEASE VOLUME AND PRESENTATION
Mar 18, 2026, 21:38 PM -
NATIONAL TRENDS IN STATIN AND EZETIMIBE USE AND CARDIOVASCULAR RISK AMONG U.S. ADULTS WITH HYPERLIPIDEMIA: MEPS 2018-2023
Mar 18, 2026, 21:38 PM -
POPULATION PHARMACOKINETIC MODELING OF A NOVEL ONCE-DAILY LITHIUM CARBONATE EXTENDED RELEASE (XR) BI-LAYER MATRIX FORMULATION TO SUPPORT FORMULATION SWITCHING AND PEDIATRIC DOSING
Mar 18, 2026, 21:38 PM -
HEALTHCARE RESOURCE UTILIZATION AMONG PEDIATRIC POPULATIONS BY WEIGHT STATUS
Mar 18, 2026, 21:38 PM -
TREATMENT PATTERN IN PATIENTS WITH ADVANCED BREAST CANCER AFTER CDK4/6I FAILURE IN CHINA
Mar 18, 2026, 21:38 PM -
DISPARITIES BY SOCIOECONOMIC STATUS IN TIME FROM DIAGNOSIS TO CURATIVE SURGICAL TREATMENT FOR EARLY-STAGE NON-SMALL CELL LUNG CANCER IN U.S. ADULTS
Mar 18, 2026, 21:38 PM -
QUANTIFYING THE LIFETIME HEALTH AND SOCIETAL BENEFITS OF TIMELY DIAGNOSIS AND ACCESS TO APPROVED TREATMENTS IN ANTI-ACETYLCHOLINE RECEPTOR ANTIBODY-POSITIVE (ACHR-AB+) GENERALIZED MYASTHENIA GRAVIS (GMG) IN THE UNITED STATES
Mar 18, 2026, 21:38 PM -
A COST-CONSEQUENCE ANALYSIS OF NOGAPENDEKIN ALFA INBAKICEPT-PMLN (NAI) IN COMBINATION WITH BACILLUS CALMETTE-GUÉRIN (BCG) VERSUS TAR-200 FOR BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU±PAPILLARY DISEASE (NMIBC CIS)
Mar 18, 2026, 21:38 PM
